Turn Therapeutics Inc. in brief
Turn Therapeutics Inc. is a listed company in the Biotechnology industry, based in Westlake Village, California, USA. Its shares trade under the symbol TTRX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Turn Therapeutics Inc.
Turn Therapeutics is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Our lead program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula.
GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema. We intend to conduct an interim assessment at approximately 50% trial completion. Topline results are expected mid-2026.
From the company's annual report filed with the US SEC: read the report
Turn Therapeutics Inc. timeline
- 2024
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2025
- ✎Renamed Turn Therapeutics Inc.Formerly Global Health Solutions, Inc.
- 🔔Initial public offeringFinal prospectus filed with the SEC on 8 October 2025; shares registered for exchange trading on 29 September 2025.
Events of Turn Therapeutics Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-6M | $-3M | — |
| Dec 2024 | — | — | $-2M | $-2M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-3M | — | — | $-0.12 | — |
| Dec 2024 | $-1M | — | — | $-0.07 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 20268-KCurrent reportRegulation FD disclosure
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Oct 19, 2026DEF 14AProxy statement
- Oct 7, 20268-KCurrent reportRegulation FD disclosure
- Sep 10, 20268-KCurrent reportRegulation FD disclosure
- Sep 9, 20268-KCurrent reportRegulation FD disclosure
- Aug 18, 20268-KCurrent reportUnregistered share sale
- Aug 17, 20268-KCurrent reportRegulation FD disclosure
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jul 28, 20268-KCurrent reportRegulation FD disclosure
Official filings of Turn Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-6 M
- Net income
- $-3 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $12 M
- Total liabilities
- $7 M
- Total equity
- $5 M
As of December-2025
Top 43 institutional investors in Turn Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 423,893 | +349,592 (+470.51%) | 1.39% | $6 M | Nov 13, 2026 |
| 2 | BlackRock, Inc. | 259,028 | +220,437 (+571.21%) | 0.85% | $4 M | Nov 13, 2026 |
| 3 | SteelPeak Wealth, LLC | 251,275 | +1,819 (+0.73%) | 0.82% | $4 M | Oct 16, 2026 |
| 4 | Ieq Capital, LLC | 227,396 | 0 (0.00%) | 0.74% | $3 M | Nov 10, 2026 |
| 5 | Millennium Management LLC | 167,802 | +107,251 (+177.13%) | 0.55% | $2 M | Nov 16, 2026 |
| 6 | Geode Capital Management, LLC | 158,631 | +141,489 (+825.39%) | 0.52% | $2 M | Nov 6, 2026 |
| 7 | Morgan Stanley | 139,674 | +128,327 (+1130.93%) | 0.46% | $2 M | Nov 13, 2026 |
| 8 | DDFG, Inc | 111,379 | +3,550 (+3.29%) | 0.36% | $2 M | Oct 15, 2026 |
| 9 | Susquehanna International Group, LLP | 94,076 | New | 0.31% | $1 M | Nov 16, 2026 |
| 10 | HRT Financial LP | 57,450 | New | 0.19% | $1 M | Nov 13, 2026 |
| 11 | Vanguard Fiduciary Trust Co | 36,048 | +23,568 (+188.85%) | 0.12% | $1 M | Nov 13, 2026 |
| 12 | Aaron Wealth Advisors LLC | 32,564 | 0 (0.00%) | 0.11% | $0 M | Oct 13, 2026 |
| 13 | Northern Trust Corp | 30,762 | New | 0.10% | $0 M | Nov 16, 2026 |
| 14 | Tamar Securities, LLC | 30,000 | 0 (0.00%) | 0.10% | $0 M | Nov 3, 2026 |
| 15 | Goldman Sachs Group Inc | 27,510 | New | 0.09% | $0 M | Nov 16, 2026 |
| 16 | Bridgewater Advisors Inc. | 25,326 | -2,000 (-7.32%) | 0.08% | $0 M | Nov 16, 2026 |
| 17 | HighTower Advisors, LLC | 24,279 | +4,595 (+23.34%) | 0.08% | $0 M | Nov 10, 2026 |
| 18 | Brown Brothers Harriman & Co | 23,688 | 0 (0.00%) | 0.08% | $0 M | Nov 13, 2026 |
| 19 | Charles Schwab Investment Management Inc | 16,310 | New | 0.05% | $0 M | Nov 16, 2026 |
| 20 | Jefferies Financial Group Inc. | 16,300 | 0 (0.00%) | 0.05% | $0 M | Nov 5, 2026 |
| 21 | LPL Financial LLC | 16,100 | +5,800 (+56.31%) | 0.05% | $0 M | Nov 6, 2026 |
| 22 | McCarthy Asset Management, Inc. | 15,018 | 0 (0.00%) | 0.05% | $0 M | Oct 20, 2026 |
| 23 | Jump Financial, LLC | 14,944 | New | 0.05% | $0 M | Nov 13, 2026 |
| 24 | Bank Of America Corp /de/ | 14,124 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 25 | Barclays PLC | 13,748 | New | 0.04% | $0 M | Nov 6, 2026 |
Show all 43: investors 26 to 43
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | ExodusPoint Capital Management, LP | 12,098 | New | 0.04% | $0 M | Nov 16, 2026 |
| 27 | Schonfeld Strategic Advisors LLC | 11,214 | New | 0.04% | $0 M | Nov 16, 2026 |
| 28 | Jane Street Group, LLC | 11,131 | New | 0.04% | $0 M | Nov 12, 2026 |
| 29 | Qube Research & Technologies Ltd | 10,941 | New | 0.04% | $0 M | Nov 13, 2026 |
| 30 | Composition Wealth, LLC | 10,000 | -6,000 (-37.50%) | 0.03% | $0 M | Nov 10, 2026 |
| 31 | Cannon Financial Strategists, Inc. | 10,000 | 0 (0.00%) | 0.03% | $0 M | Oct 19, 2026 |
| 32 | Vanguard Global Advisers, LLC | 6,383 | New | 0.02% | $0 M | Nov 13, 2026 |
| 33 | Aster Capital Management (DIFC) Ltd | 5,235 | New | 0.02% | $0 M | Nov 12, 2026 |
| 34 | Citigroup Inc | 4,723 | New | 0.02% | $0 M | Nov 4, 2026 |
| 35 | TD Waterhouse Canada Inc. | 3,059 | New | 0.01% | $0 M | Oct 16, 2026 |
| 36 | Tower Research Capital LLC (TRC) | 2,671 | New | 0.01% | $0 M | Nov 16, 2026 |
| 37 | UBS Group AG | 2,627 | +364 (+16.08%) | 0.01% | $0 M | Nov 10, 2026 |
| 38 | Blue Trust, Inc. | 1,122 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 39 | Wells Fargo & Company/mn | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 40 | Royal Bank Of Canada | 408 | -27,842 (-98.56%) | 0.00% | $0 M | Nov 16, 2026 |
| 41 | Pflug Koory, LLC | 170 | 0 (0.00%) | 0.00% | $0 M | Oct 26, 2026 |
| 42 | Caitong International Asset Management Co., Ltd | 15 | -16 (-51.61%) | 0.00% | $0 M | Oct 29, 2026 |
| 43 | Parkside Financial Bank & Trust | 10 | New | 0.00% | $0 M | Oct 27, 2026 |
Mutual funds holding Turn Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 62,749 | $0 M | 0.21% | <0.01% | +85% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 36,232 | $0 M | 0.12% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 17,142 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 9,897 | $0 M | 0.03% | <0.01% | −36% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,359 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,244 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 129 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Turn Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Bradley Evan BurnamChief Executive Officer, Director, 10% owner | Giftindirect | -300,000 | — | — | 15.42 M | Form 4 |
| filed | Bradley Evan BurnamChief Executive Officer, Director, 10% owner | Giftindirect | +300,000 | — | — | 300,000 | Form 4 |
| filed | Bradley Evan BurnamChief Executive Officer, Director, 10% owner | Giftindirect | -300,000 | — | — | 15.12 M | Form 4 |
| filed | Bradley Evan BurnamChief Executive Officer, Director, 10% owner | Giftindirect | +300,000 | — | — | 300,000 | Form 4 |
| filed | BEB Holdings, LLC10% owner | Giftindirect | -300,000 | — | — | 15.72 M | Form 4 |
| filed | Arthur F. GoldenDirector | Gift | +300,000 | — | — | 360,602 | Form 4 |
| filed | Martin William DewhurstDirector | Grant or award | +21,882 | — | — | 21,882 | Form 4 |
| filed | Zuraiz ChaudharySee Remarks | Buy | +2,500 | $3.500 | $9 K | 12,500 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Turn Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $11.65, raising $208.2M · IPO calendar
Trading halts
- 2025-10-24 18:41 UTC, code LUDP, resumed 18:46 UTC
- 2025-10-09 14:23 UTC, code LUDP, resumed 14:28 UTC
- 2025-10-09 13:52 UTC, code LUDP, resumed 13:57 UTC
- 2025-10-09 13:42 UTC, code LUDP, resumed 13:47 UTC
- 2025-10-08 15:53 UTC, code LUDP, resumed 15:58 UTC
Fails to deliver
- : 116 shares at $10.61
- : 116 shares at $10.28
- : 3,200 shares at $10.47
- : 5,157 shares at $11.39
- : 88 shares at $14.39
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Turn Therapeutics Inc. scorecard#
Passes 0 of the 5 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.12 vs -0.07Diluted EPS -0.12 in fiscal 2025 against -0.07 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-141.5%-141.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 1
- ✗Short-term assets cover short-term liabilities0.9×Current ratio 0.87 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year4.0%Diluted shares up 4.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Turn Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 |
|---|---|---|---|
| Income statement | |||
| Research and development | 266+8.0%— | 246—— | |
| General and administrative | 5,593+261%— | 1,551—— | |
| Operating expenses | 5,859+226%— | 1,797—— | |
| Operating income | −5,859—— | −1,797—— | |
| Interest and finance income | 30+3.0%— | 29—— | |
| Other non-operating income (expense) | 2,665+9181%— | 29—— | |
| Net income attributable to shareholders | −3,194—— | −1,768—— | |
| Earnings per share, basic | -0.12—— | -0.07—— | |
| Earnings per share, diluted | -0.12—— | -0.07—— | |
| Shares, weighted average (basic) | 28+4.0%— | 27—— | |
| Shares, weighted average (diluted) | 28+4.0%— | 27—— | |
| Balance sheet | |||
| Cash and cash equivalents | 4,028+708%33.1% | 498—24.3% | |
| Other current assets | 120−46.6%1.0% | 225—11.0% | |
| Current assets | 5,196+373%42.7% | 1,098—53.6% | |
| Right-of-use (leased) assets | 79−34.7%0.6% | 120—5.9% | |
| Other intangible assets | 922+12.2%7.6% | 822—40.1% | |
| Total assets | 12,162+494%100% | 2,049—100% | |
| Current liabilities | 6,003+748%49.4% | 708—34.6% | |
| Lease liabilities (non-current) | 34−57.6%0.3% | 80—3.9% | |
| Total liabilities | 7,476+236%61.5% | 2,226—109% | |
| Retained earnings | −22,390—−184% | −19,196—−937% | |
| Shareholders' equity | 4,687—38.5% | −177—−8.7% | |
| Total liabilities and equity | 12,162+494%100% | 2,049—100% | |
| Shares outstanding | 29+9.7%— | 27—— | |
| Cash-flow statement | |||
| Depreciation and amortization | 53+11.1%— | 47—— | |
| Share-based compensation | 419+18.8%— | 353—— | |
| Cash from operating activities | −2,563—— | −1,361—— | |
| Intangible assets bought | −153—— | −99—— | |
| Cash from investing activities | −153—— | −99—— | |
| Shares issued | 6,919+500%— | 1,152—— | |
| Cash from financing activities | 6,919+500%— | 1,152—— | |
| Report | 10-K | 10-K | |
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 1,225—— | 605+281%— | 475—— | 109—— | 35*—— | 159—— | |
| General and administrative | 5,828—— | 1,379−21.4%— | 1,153—— | 1,137—— | 2,159*—— | 1,755—— | |
| Operating expenses | 7,052—— | 1,984+3.7%— | 1,628—— | 1,246—— | 2,194*—— | 1,914—— | |
| Operating income | −7,052—— | −1,984—— | −1,628—— | −1,246—— | −2,194*—— | −1,914—— | |
| Interest and finance income | — | 84+1543%— | — | 50—— | 14*—— | 5.1—— | |
| Interest expense and finance costs | — | 341—— | — | — | — | — | |
| Other non-operating income (expense) | −5,720—— | −4,246−45415%— | −4,222—— | 275—— | 2,473*—— | 9.4—— | |
| Net income attributable to shareholders | −12,773—— | −6,231—— | −5,850r−5,850—— | −971—— | 279*—— | −1,904—— | |
| Earnings per share, basic | — | -0.21—— | -0.20—— | -0.03—— | — | -0.07—— | |
| Earnings per share, diluted | — | -0.21—— | -0.20—— | -0.03—— | — | -0.07—— | |
| Shares, weighted average (basic) | 30—— | 30+7.7%— | 30—— | 29—— | — | 28—— | |
| Shares, weighted average (diluted) | 30—— | 30+7.7%— | 30—— | 29—— | — | 28—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 9,433—57.7% | 9,433+1736%57.7% | 9,949—58.7% | 11,010—59.1% | 4,028—33.1% | 514—12.0% | |
| Other current assets | 103—0.6% | 103−45.1%0.6% | 140—0.8% | 235—1.3% | 120—1.0% | 189—4.4% | |
| Current assets | 11,081—67.8% | 11,081+236%67.8% | 10,428—61.5% | 11,453—61.4% | 5,196—42.7% | 3,295—76.7% | |
| Right-of-use (leased) assets | 45—0.3% | 45−50.0%0.3% | 56—0.3% | 68—0.4% | 79—0.6% | 89—2.1% | |
| Other intangible assets | 913—5.6% | 913+0.9%5.6% | 911—5.4% | 920—4.9% | 922—7.6% | 905—21.1% | |
| Total assets | 16,350—100% | 16,350+280%100% | 16,961—100% | 18,644—100% | 12,162—100% | 4,298—100% | |
| Debt due within a year | 444—2.7% | 444—2.7% | — | — | — | — | |
| Current liabilities | 3,479—21.3% | 3,479+50.6%21.3% | 8,764—51.7% | 5,131—27.5% | 6,003—49.4% | 2,309—53.7% | |
| Long-term debt | 5,741—35.1% | 5,741—35.1% | 6,063—35.7% | 5,937—31.8% | — | — | |
| Lease liabilities (non-current) | — | — | 8.7—0.1% | 22—0.1% | 34—0.3% | 46—1.1% | |
| Total liabilities | 10,658—65.2% | 10,658+181%65.2% | 16,274—96.0% | 12,527—67.2% | 7,476—61.5% | 3,794—88.3% | |
| Retained earnings | −35,442—−217% | −35,442—−217% | −29,211—−172% | −23,361—−125% | −22,390—−184% | −22,669—−527% | |
| Shareholders' equity | 5,692—34.8% | 5,692+1029%34.8% | 687—4.0% | 6,118—32.8% | 4,687—38.5% | 504r504—11.7% | |
| Total liabilities and equity | 16,350—100% | 16,350+280%100% | 16,961—100% | 18,644—100% | 12,162—100% | 4,298—100% | |
| Shares outstanding | 31—— | 31+9.0%— | 30—— | 30—— | 29—— | 28—— | |
| Cash-flow statement | |||||||
| Share-based compensation | 1,670—— | 713*—— | 419*—— | 281—— | 256*—— | — | |
| Cash from operating activities | −5,282—— | −1,549*—— | −923*—— | −1,633—— | −1,176*—— | — | |
| Intangible assets bought | −66—— | −16*—— | −5.8*—— | −12—— | −31*—— | — | |
| Cash from investing activities | −66—— | −16*—— | −5.8*—— | −12—— | −31*—— | — | |
| Shares issued | — | — | — | — | 3,772r3,178*—— | — | |
| Cash from financing activities | 12,605—— | 1,641*—— | 0.0*—— | 7,787—— | 3,178*—— | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Turn Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 3 · New debt 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $2 M | Private placement after listing | Under $2 million | 8 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Turn Therapeutics Inc.#
$0 spent on lobbying the US Congress and federal agencies in 2021.
Lobbying firms hired in 2021
CONNECT STRATEGY LLC · Turnberry Solutions, LLC
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2021 | $0 | — | 3 |
| 2020 | $10 K | — | 3 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Turn Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Turn Therapeutics Inc.🇺🇸 | — | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Turn Therapeutics Inc.? Verify and update this profile — free
Show Turn Therapeutics Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.